• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为组蛋白去乙酰化酶抑制剂的抗癌钌和铑钢琴凳配合物。

Anticancer Ru and Rh Piano-Stool Complexes that are Histone Deacetylase Inhibitors.

作者信息

Cross Jasmine M, Blower Tim R, Gallagher Natalie, Gill Jason H, Rockley Kimberly L, Walton James W

机构信息

Department of Chemistry, Durham University, South Road, Durham, DH1 3LE, United Kingdom.

School of Biological and Biomedical Sciences, Durham University, South Road, Durham, DH1 3LE, United Kingdom.

出版信息

Chempluschem. 2016 Dec;81(12):1276-1280. doi: 10.1002/cplu.201600413. Epub 2016 Oct 12.

DOI:10.1002/cplu.201600413
PMID:31964062
Abstract

The first examples of Ru and Rh piano-stool complex histone deacetylase (HDAC) inhibitors are presented. The novel complexes have antiproliferative activity against H460 non-small-cell lung carcinoma cells that is comparable to the clinically used HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). Strong evidence for HDAC inhibition as a primary mechanism of action is provided. The complexes reported here represent an important step towards the design of highly active and selective HDAC inhibitors.

摘要

首次展示了钌(Ru)和铑(Rh)钢琴凳型配合物组蛋白去乙酰化酶(HDAC)抑制剂的实例。这些新型配合物对H460非小细胞肺癌细胞具有抗增殖活性,与临床使用的HDAC抑制剂辛二酰苯胺异羟肟酸(SAHA)相当。提供了HDAC抑制作为主要作用机制的有力证据。本文报道的配合物代表了设计高活性和选择性HDAC抑制剂的重要一步。

相似文献

1
Anticancer Ru and Rh Piano-Stool Complexes that are Histone Deacetylase Inhibitors.作为组蛋白去乙酰化酶抑制剂的抗癌钌和铑钢琴凳配合物。
Chempluschem. 2016 Dec;81(12):1276-1280. doi: 10.1002/cplu.201600413. Epub 2016 Oct 12.
2
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.具有组蛋白去乙酰化酶亚型选择性的抗癌钌配合物。
Molecules. 2020 May 21;25(10):2383. doi: 10.3390/molecules25102383.
3
Histone deacetylase inhibitors: development as cancer therapy.组蛋白去乙酰化酶抑制剂:作为癌症治疗手段的发展
Novartis Found Symp. 2004;259:269-81; discussion 281-8.
4
Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.组蛋白去乙酰化酶抑制剂的结构要求:基于异羟肟酸修饰的SAHA类似物
Arch Pharm (Weinheim). 2016 May;349(5):373-82. doi: 10.1002/ardp.201500472. Epub 2016 Apr 9.
5
Non-hydroxamate histone deacetylase inhibitors.非异羟肟酸类组蛋白去乙酰化酶抑制剂
Curr Med Chem. 2005;12(24):2867-80. doi: 10.2174/092986705774454706.
6
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.组蛋白脱乙酰酶抑制剂辛二酰苯胺异羟肟酸(伏立诺他)和丙戊酸可诱导人结肠癌细胞产生不可逆且不依赖多药耐药基因1(MDR1)的耐药性。
Int J Oncol. 2007 Sep;31(3):633-41.
7
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.司立他汀和辛二酰苯胺异羟肟酸是组蛋白脱乙酰酶抑制剂,在体外具有强大的抗弓形虫活性。
J Parasitol. 2007 Jun;93(3):694-700. doi: 10.1645/GE-1043R.1.
8
Histone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents.组蛋白去乙酰化酶靶向荧光钌(II)多吡啶配合物作为有效的抗癌药物。
Chemistry. 2013 Jul 29;19(31):10160-9. doi: 10.1002/chem.201300814. Epub 2013 Jul 4.
9
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.组蛋白去乙酰化酶抑制剂的结构要求:C4修饰的SAHA类似物具有HDAC6/HDAC8双重选择性。
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
10
Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes.丁酰肼,一种有效的组蛋白去乙酰化酶抑制剂;其 X 射线晶体结构和 Zn(II)、Ni(II)、Cu(II) 和 Fe(III)配合物的固态和溶液研究。
J Inorg Biochem. 2011 Jun;105(6):763-9. doi: 10.1016/j.jinorgbio.2011.03.003. Epub 2011 Mar 22.

引用本文的文献

1
Evaluation of newly synthesized schiff base Pd(II) complexes for prostate cancer treatment through cytotoxicity and molecular mechanistic studies.通过细胞毒性和分子机制研究评估新合成的席夫碱钯(II)配合物用于前列腺癌治疗的效果。
Front Chem. 2025 Jul 17;13:1636477. doi: 10.3389/fchem.2025.1636477. eCollection 2025.
2
Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents.含锌金属酶:金属基抗癌剂的抑制作用
Front Chem. 2020 May 19;8:402. doi: 10.3389/fchem.2020.00402. eCollection 2020.
3
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.
具有组蛋白去乙酰化酶亚型选择性的抗癌钌配合物。
Molecules. 2020 May 21;25(10):2383. doi: 10.3390/molecules25102383.
4
Bioactive Salen-type Schiff Base Transition Metal Complexes as Possible Anticancer Agents.生物活性萨伦型席夫碱过渡金属配合物作为潜在的抗癌剂
Iran J Pharm Res. 2019 Fall;18(4):2055-2066. doi: 10.22037/ijpr.2019.12792.11151.